References:
1. Montalescot, G., et al. . 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. EUR HEART J 34 , 2949-3003 (2013).
2. Falase, B., Easaw, J. & Youhana, A. The role of nicorandil in the treatment of myocardial ischaemia. Expert Opin Pharmacother 2 , 845-856 (2001).
3. Krumenacker, M. & Roland, E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 20 Suppl 3 , S93-S102 (1992).
4. Refaie, M., Shehata, S., El-Hussieny, M., Abdelraheem, W.M. & Bayoumi, A. Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity. CARDIOVASC TOXICOL 20 , 71-81 (2020).
5. Taira, N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 10 Suppl 8 , S1-S9 (1987).
6. Roland, E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. EUR HEART J 14 Suppl B , 48-52 (1993).
7. Walker, A., et al. . Economic evaluation of the impact of nicorandil in angina (IONA) trial. HEART 92 , 619-624 (2006).
8. Horinaka, S., et al. . Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. CIRC J 74 , 503-509 (2010).
9. Ferrari, R., et al. . Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. EUR HEART J40 , 190-194 (2019).
10. Shi, L., Chen, L., Qi, G., Tian, W. & Zhao, S. Effects of Intracoronary Nicorandil on Myocardial Microcirculation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs 20 , 191-198 (2020).
11. Kasama, S., et al. . Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J NUCL MED 48 , 1676-1682 (2007).
12. Ito, H., et al. . Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J AM COLL CARDIOL 33 , 654-660 (1999).
13. Ueda, H., et al. . Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. CAN J CARDIOL 20 , 625-629 (2004).
14. Falase, B., Easaw, J. & Youhana, A. The role of nicorandil in the treatment of myocardial ischaemia. Expert Opin Pharmacother 2 , 845-856 (2001).
15. Waldron, G.J. & Cole, W.C. Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Clin Exp Pharmacol Physiol26 , 180-184 (1999).
16. Iwaki, F., Amano, H. & Ohura, K. Nicorandil inhibits osteoclast differentiation in vitro. EUR J PHARMACOL 793 , 14-20 (2016).
17. Li, W., Wu, N., Shu, W., Jia, D. & Jia, P. Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats. EXP THER MED 10 , 2197-2205 (2015).
18. Lee, J.M., et al. . Safety and efficacy of intracoronary nicorandil as hyperaemic agent for invasive physiological assessment: a patient-level pooled analysis. EUROINTERVENTION 12 , e208-e215 (2016).
19. Shirakabe, A., et al. . Efficacy and safety of nicorandil therapy in patients with acute heart failure. J CARDIOL 56 , 339-347 (2010).